ERK inhibitors
US9988397B2 · kind B2 · utility
1Cited by
0References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 10, 2015 |
| Grant date | Jun 5, 2018 |
| Priority date | — |
| Expiry date | Dec 20, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.